Rein Therapeutics receives EMA authorization to begin Phase 2 trial of LTI-03 for IPF

Rein Therapeutics, Inc.

European Medicines Agency approved Phase 2 RENEW trial at clinical sites in Germany and Poland.
Global randomized, double-blind, placebo-controlled study will enroll up to 120 IPF patients over 24 weeks.
LTI-03 is a Caveolin-1-derived peptide designed to inhibit fibrosis and support lung tissue regeneration.
Company previously received UK MHRA clearance; trial will evaluate safety, tolerability, and efficacy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.